Moderna, Inc. (MRNA)
After hours:
| Previous Close | 102.00 |
| Open | 102.37 |
| Bid | 101.29 x 400 |
| Ask | 101.44 x 400 |
| Day's Range | 100.45 - 103.79 |
| 52 Week Range | 62.55 - 142.79 |
| Volume | |
| Avg. Volume | 3,756,544 |
| Market Cap | 38.828B |
| Beta (5Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Moderna (MRNA) Stock Moves -0.58%: What You Should Know
Moderna (MRNA) reachead $101.41 at the closing of the latest trading day, reflecting a -0.58% change compared to its last close.
- Investor's Business Daily
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Moderna stock is under pressure and estimates have come down for its first quarter. Is MRNA stock now a sell?
- Reuters
FOCUS-China's drugmakers can't sell mRNA shots but haven't quit yet
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. Three Chinese companies - Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics - came up with mRNA vaccines that won limited emergency approvals in Asia. However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health official told Reuters.
